StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Ashish Kyal, Waves Strategy Advisors

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byAshish Kyal, Waves Strategy AdvisorsHorizon: NA (inferred Swing (≤2wk))24 Sept 2026via ET Now (Live)

Entry₹1,175Inferred
Target₹1,220
Total upside +3.83% (call closed)
Stop loss₹1,140-2.98% risk
Exit₹1,22028 Sept 2026, 9:50 am
Target hit+3.83%0.00%upside left
Follow Ashish Kyal for new calls(30% target hit, 182 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 282 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 28 Sept 2026
5 supporting1 neutral0 opposing
Supports the BUY call (5)

2 advisors have active intraday BUY calls on this stock, with 1 issued in the last 14 days

Advisor consensus · adjacent horizon·28 Sept · today

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·28 Sept · today

Zydus Lifesciences says USFDA inspection at New Jersey office concludes with nil observations

NewsCnbc-Tv18·26 Sept · yesterday

(opens in new tab)

The USFDA inspection of Zydus Lifesciences' USA office for pharmacovigilance and post-marketing systems concluded with no observations.

BSE · Company Update·26 Sept · yesterday

(opens in new tab)

Bernstein bets on this drugmaker for 28% upside citing a key value driver for the future

NewsCnbc-Tv18·18 Sept · 1w ago

(opens in new tab)
Neutral / worth noting (1)

Zydus Lifesciences (NSE:ZYDUSLIFE): Why Did It Publish a Lost Share Certificate Notice?

NewsGoogle News·24 Sept · 3d ago

(opens in new tab)
Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Ashish Kyal, Waves Strategy Advisors

Every call and its outcome